Skip to main content
Publications
Marsal JR , Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights . Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Suades-Gonzalez E, Forns J , Garcia-Esteban R , Lopez-Vicente M, Esnaola M, Alvarez-Pedrerol M, Julvez J, Caceres A, Basagana X, Lopez-Sala A, Sunyer J. A longitudinal study on attention development in primary school children with and without teacher-reported symptoms of ADHD . Front Psychol. 2017 May 16;8:655. doi: 10.3389/fpsyg.2017.00655
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043